Radiation and Chemotherapy After Surgery as a Viable Alternative to Radical Cystectomy in Recurrent Bladder Cancer – NRG Oncology

NRG Oncology shared a post on LinkedIn:

“Press release: NRG Oncology Study Results Indicate that Radiation and Chemotherapy After Surgery Could be a Viable Alternative to Radical Cystectomy for Patients with Recurrent Bladder Cancer.”

Read further.
Source: NRG Oncology/LinkedIn

Douglas M. Dahl, MD, FACS, is the Chief of Urologic Oncology and a urologic surgeon at Massachusetts General Hospital. He specializes in the treatment of genitourinary cancers, minimally invasive surgical techniques, and related research. He serves as the Chief of the Division of Urologic Oncology, Clinical Co-Director of The Claire and John Bertucci Center for Genitourinary Cancers, and is also an Associate Urologist.